What caused the intraday drop in MDG1.DE stock?

The intraday drop to **€0.1335** accompanied heavy volume **189,470**, reflecting a mix of profit taking and liquidity-driven selling. Small-cap biotech volatility and limited market depth amplified the move, not a single disclosed corporate event.

Is MDG1.DE stock a buy after the dip?

MDG1.DE stock may offer a short-term oversold bounce, but long-term buyers should consider negative EPS, cash burn and pipeline risk. Traders should use small sizes, tight stops and confirm buying on improving volume or concrete clinical updates.

What targets should traders use for an oversold bounce in MDG1.DE stock?

Tactical intraday target is the day high **€0.1595** (+**19.49%**). A near-term bounce target is **€0.20** (+**49.81%**). Use stops under the session low **€0.0782** and size positions to risk tolerance.

DE Stocks

MDG1.DE Medigene AG XETRA -27.64% intraday 23 Jan 2026: Oversold bounce at €0.13

ByHuzaifa Zahoor January 23, 2026

MDG1.DE stock dropped 27.64% intraday to €0.1335 on XETRA on 23 Jan 2026, triggering an oversold bounce setup we are watching closely. The move came on volume 189,470, almost 4.39x the 50-day average, and pushed the price toward the session low of €0.0782. Traders using intraday bounce strategies should note the gap from the 50-day average (€1.41) and the stretched valuation metrics. This note breaks down technicals, fundamentals, short-term targets and a measured trade plan for an oversold bounce approach.